Introduction: Venous thromboembolism (VTE) constitutes a major healthcare burden in the United States (US), despite being effectively prevented by VTE prophylaxis. However, many patients at risk for VTE receive inadequate prophylaxis, and this has prompted the development of national performance measures to help improve prescribing practices. This study investigates the rates of post-operative VTE prevention in a real-world population of commercially-insured US surgical patients, and identifies VTE risk factors in this group.

Methods: Discharges from the PharMetrics database (January 2001–December 2005) that had ICD-9 codes for orthopedic or abdominal surgery and were aged ≥18 years were included in the study. Patients aged ≥65 years and not in a Medicare Risk group and those without complete records or health plan coverage were excluded. The primary outcome measure for this study was the rate of (and time to) symptomatic VTE following surgery (as identified by ICD-9 codes), and the secondary outcome measure was the identification of independent VTE risk factors using logistic regression analysis to control for patient and hospital characteristics.

Results: 172,320 discharges met the study criteria, of which 23.9% underwent orthopedic surgery and 76.1% underwent abdominal surgery. Primary outcome measures are shown in Table 1. In summary, orthopedic discharges had a higher incidence of clinically symptomatic VTE (4.7%) than abdominal discharges (3.1%). Both types of surgery had a similar distribution of VTE into deep-vein thrombosis (DVT, 72.5–75.0% of all VTE respectively), pulmonary embolism (PE, 22.5–25.0% of all VTE respectively), or both DVT and PE (2.5% of all VTE). The median time to a VTE event was shorter in orthopedic discharges (median 30 days) than their abdominal surgery counterparts (median 65 days). When considering all discharges in a logistic regression analysis, a prior history of VTE was found to be the strongest independent predictor of VTE (odds ratio [OR] 10.2; 95% confidence interval [CI] 9.2–11.4; p<0.001). Other significant variables associated with VTE outcomes included orthopedic surgery rather than abdominal surgery (OR 1.4; 95% CI 1.4–1.6), increasing age (per year) (OR 1.02; 95% CI 1.01–1.02), male gender (OR 1.18; 95% CI 1.09–1.28), increasing index hospitalization length of stay (per day) (OR 1.06; 95% CI 1.05–1.06), and pre-index Charlson comorbidity index (OR 1.12; 95% CI 1.09–1.14).

Conclusions: Many patients undergoing orthopedic or abdominal surgery are at risk for VTE, with approximately 1 in 25 patients in this analysis experiencing a clinical VTE event. Improved implementation of national performance measures may help reduce the overall burden of VTE in the United States.

Table 1 – VTE event rates

Total (N=172,320)Orthopedic Surgery (N=41,139)Abdominal Surgery (N=131,181)
Event, n (%)    
VTE 5956 (3.5) 1944 (4.7) 4012 (3.1) 
DVT 4367 (2.5) 1458 (3.5) 2909 (2.2) 
PE 1439 (0.8) 438 (1.1) 1001(0.8) 
DVT + PE 150 (0.1) 48 (0.1) 102 (0.1) 
Time to VTE Event: (days, median)    
VTE 51 30 65 
DVT 70 34 83 
PE 46 20 26 
DVT+PE 31 17 27.5 
Total (N=172,320)Orthopedic Surgery (N=41,139)Abdominal Surgery (N=131,181)
Event, n (%)    
VTE 5956 (3.5) 1944 (4.7) 4012 (3.1) 
DVT 4367 (2.5) 1458 (3.5) 2909 (2.2) 
PE 1439 (0.8) 438 (1.1) 1001(0.8) 
DVT + PE 150 (0.1) 48 (0.1) 102 (0.1) 
Time to VTE Event: (days, median)    
VTE 51 30 65 
DVT 70 34 83 
PE 46 20 26 
DVT+PE 31 17 27.5 

Disclosures: Spyropoulos:sanofi-aventis: Consultancy; Eisai Inc: Speakers Bureau. Hussein:sanofi-aventis: employee of IMS Health which received funding to perform the research from sanofi-aventis. Lin:sanofi-aventis: Employment, Financial and editorial support for this publication was provided by sanofi-aventis US, Inc.. Battleman:sanofi-aventis: employee of IMS Health which received funding to perform the research from sanofi-aventis.

Author notes

Corresponding author

Sign in via your Institution